Elevated urinary level of vitamin D‑binding protein as a novel biomarker for diabetic nephropathy

Tian,Xiao-Qin; Zhao,Li-Min; Ge,Jia-Pu; Zhang,Yan; Xu,Yan-Cheng

doi:10.3892/etm.2013.1426

Elevated urinary level of vitamin D‑binding protein as a novel biomarker for diabetic nephropathy

Authors:
- Xiao-Qin Tian
- Li-Min Zhao
- Jia-Pu Ge
- Yan Zhang
- Yan-Cheng Xu
View Affiliations

Affiliations: Department of Endocrinology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Endocrinology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang 830011, P.R. China, Department of Endocrinology, Traditional Chinese Medicine Hospital, Xinjiang Medical University, Urumqi, Xinjiang 830000, P.R. China
Published online on: November 26, 2013 https://doi.org/10.3892/etm.2013.1426
Pages: 411-416

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Improving the early prediction and detection of diabetic nephropathy (DN) remains a great challenge in disease management. The aim of this study was to evaluate the early detection power of urinary vitamin D‑binding protein (VDBP) for the diagnosis of DN. Urine samples were obtained from 45 healthy volunteers and 105 diabetic patients with normoalbuminuria (DM group), microalbuminuria (DN1 group) and macroalbuminuria (DN2 group) (n=35 per group). The VDBP expression patterns in urine from patients and controls were quantified by western blot analysis. The excretion levels of urinary VDBP were quantified with enzyme-linked immunosorbent assay. The quantification results were obtained by correcting for creatinine expression and showed that urinary VDBP levels were significantly elevated in the patients of the DN1 and DN2 groups compared with those of the DM group and normal controls (1,011.33±325.30 and 1,406.34±239.66 compared with 466.54±213.63 and 125.48±98.27 ng/mg, respectively) (P<0.001). Receiver operating characteristic analysis of urinary VDBP levels for the diagnosis of DN rendered an optimum cut-off value of 552.243 ng/mg corresponding to 92.86% sensitivity and 85.00% specificity, which also showed an area under the ROC curve of 0.966. In conclusion, the findings of the present study suggest that urinary VDBP may be a potential biomarker for the early detection and prevention of DN. Further studies are required to examine the pathogenic mechanisms of elevated VDBP levels and their role in the diagnosis of DN.

View Figures

View References

1	Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG and Willett WC: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 345:790–797. 2001. View Article : Google Scholar : PubMed/NCBI
2	Pittas AG, Lau J, Hu FB and Dawson-Hughes B: The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 92:2017–2029. 2007. View Article : Google Scholar : PubMed/NCBI
3	Iso H: Changes in coronary heart disease risk among Japanese. Circulation. 118:2725–2729. 2008. View Article : Google Scholar : PubMed/NCBI
4	Valmadrid CT, Klein R, Moss SE and Klein BE: The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 160:1093–1100. 2000. View Article : Google Scholar : PubMed/NCBI
5	Wild S, Roglic G, Green A, Sicree R and King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 27:1047–1053. 2004.PubMed/NCBI
6	Tabaei BP, Al-Kassab AS, Ilag LL, Zawacki CM and Herman WH: Does microalbuminuria predict diabetic nephropathy? Diabetes Care. 24:1560–1566. 2001. View Article : Google Scholar : PubMed/NCBI
7	Jiang H, Guan G, Zhang R, Liu G, Cheng J, Hou X and Cui Y: Identification of urinary soluble E-cadherin as a novel biomarker for diabetic nephropathy. Diabetes Metab Res Rev. 25:232–241. 2009. View Article : Google Scholar : PubMed/NCBI
8	Li F, Chen DN, He CW, Zhou Y, Olkkonen VM, He N, Chen W, Wan P, Chen SS, Zhu YT, Lan KJ and Tan WL: Identification of urinary Gc-globulin as a novel biomarker for bladder cancer by two-dimensional fluorescent differential gel electrophoresis (2D-DIGE). J Proteomics. 77:225–236. 2012. View Article : Google Scholar : PubMed/NCBI
9	Thrailkill KM, Jo CH, Cockrell GE, Moreau CS and Fowlkes JL: Enhanced excretion of vitamin D binding protein in type 1 diabetes: a role in vitamin D deficiency? J Clin Endocrinol Metab. 96:142–149. 2011. View Article : Google Scholar : PubMed/NCBI
10	Cho S, Choi YS, Yim SY, Yang HI, Jeon YE, Lee KE, Kim H, Seo SK and Lee BS: Urinary vitamin D-binding protein is elevated in patients with endometriosis. Hum Reprod. 27:515–522. 2012. View Article : Google Scholar : PubMed/NCBI
11	Hanley JA and McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 143:29–36. 1982. View Article : Google Scholar : PubMed/NCBI
12	Jiang H, Guan G, Zhang R, Liu G, Liu H, Hou X and Cheng J: Increased urinary excretion of orosomucoid is a risk predictor of diabetic nephropathy. Nephrology (Carlton). 14:332–337. 2009. View Article : Google Scholar : PubMed/NCBI
13	Dihazi H and Müller GA: Urinary proteomics: a tool to discover biomarkers of kidney diseases. Expert Rev Proteomics. 4:39–50. 2007. View Article : Google Scholar : PubMed/NCBI
14	Varghese SA, Powell TB, Budisavljevic MN, Oates JC, Raymond JR, Almeida JS and Arthur JM: Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol. 18:913–922. 2007. View Article : Google Scholar : PubMed/NCBI
15	Cooke NE and David EV: Serum vitamin D-binding protein is a third member of the albumin and alpha fetoprotein gene family. J Clin Invest. 76:2420–2424. 1985. View Article : Google Scholar : PubMed/NCBI
16	Chun RF, Peercy BE, Adams JS and Hewison M: Vitamin D binding protein and monocyte response to 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D: analysis by mathematical modeling. PLoS One. 7:e307732012. View Article : Google Scholar : PubMed/NCBI
17	Christakos S, Ajibade DV, Dhawan P, Fechner AJ and Mady LJ: Vitamin D: metabolism. Endocrinol Metab Clin North Am. 39:243–253. 2010. View Article : Google Scholar
18	Yamamoto N and Naraparaju VR: Vitamin D3-binding protein as a precursor for macrophage activating factor in the inflammation-primed macrophage activation cascade in rats. Cell Immunol. 170:161–167. 1996. View Article : Google Scholar : PubMed/NCBI
19	Gregory KJ, Zhao B, Bielenberg DR, Dridi S, Wu J, Jiang W, Huang B, Pirie-Shepherd S and Fannon M: Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One. 5:e134282010. View Article : Google Scholar
20	Yamamoto N, Naraparaju VR and Asbell SO: Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients. Cancer Res. 56:2827–2831. 1996.PubMed/NCBI
21	Yamamoto N, Suyama H, Nakazato H, Yamamoto N and Koga Y: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. Cancer Immunol Immunother. 57:1007–1016. 2008. View Article : Google Scholar : PubMed/NCBI
22	Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J, Melsen F, Christensen EI and Willnow TE: An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell. 96:507–515. 1999. View Article : Google Scholar : PubMed/NCBI
23	Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM and Hewison M: Extrarenal expression of 25-hydroxyvitamin D₃-1α-hydroxylase. J Clin Endocrinol Metab. 86:888–894. 2001.PubMed/NCBI
24	Colston K, Williams NJ and Cleeve HJ: Studies on vitamin D binding protein in the nephrotic syndrome. Clin Chem. 31:718–721. 1985.PubMed/NCBI
25	Vilasi A, Cutillas PR, Maher AD, Zirah SF, Capasso G, Norden AW, Holmes E, Nicholson JK and Unwin RJ: Combined proteomic and metabonomic studies in three genetic forms of the renal Fanconi syndrome. Am J Physiol Renal Physiol. 293:F456–F467. 2007. View Article : Google Scholar : PubMed/NCBI
26	Uchida M, Teranishi H, Aoshima K, Katoh T, Kasuya M and Inadera H: Elevated urinary levels of vitamin D-binding protein in the inhabitants of a cadmium polluted area, Jinzu River basin, Japan. Tohoku J Exp Med. 211:269–274. 2007. View Article : Google Scholar : PubMed/NCBI
27	Svoren BM, Volkening LK, Wood JR and Laffel LM: Significant vitamin D deficiency in youth with type 1 diabetes mellitus. J Pediatr. 154:132–134. 2009. View Article : Google Scholar : PubMed/NCBI
28	Tahrani AA, Ball A, Shepherd L, Rahim A, Jones AF and Bates A: The prevalence of vitamin D abnormalities in South Asians with type 2 diabetes mellitus in the UK. Int J Clin Pract. 64:351–355. 2010. View Article : Google Scholar : PubMed/NCBI
29	Mirković K, Doorenbos CR, Dam WA, Lambers Heerspink HJ, Slagman MC, Nauta FL, Kramer AB, Gansevoort RT, van den Born J, Navis G and de Borst MH: Urinary vitamin D binding protein: a potential novel marker of renal interstitial inflammation and fibrosis. PLoS One. 8:e558872013.PubMed/NCBI
30	Zoidakis J, Makridakis M, Zerefos PG, Bitsika V, Esteban S, Frantzi M, Stravodimos K, Anagnou NP, Roubelakis MG, Sanchez-Carbayo M and Vlahou A: Profilin 1 is a potential biomarker for bladder cancer aggressiveness. Mol Cell Proteomics. 11:M111.0094492012. View Article : Google Scholar